Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?

Willemze, R.; Ruggeri, Annalisa; Purtill, Duncan; Rodrigues, Celso Arrais; Gluckman, Éliane; Rocha, Vanderson

doi:10.1016/j.beha.2010.05.005

Cited by 21 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This limited our ability to detect differences among subgroups that may have unique sensitivities to KIR ligand compatibility. Contrasting our cohort to the two other cohorts in which this association has been previously examined, [8][9][10] ours exclusively contains recipients of double-unit transplants, and our RIC regimen was significantly more myeloablative than the RIC regimen used in the Minnesota cohort. We did not in our study conduct KIR genotyping on donor units or conduct functional studies for the presence of recipient-reactive donor NK cells.…”

mentioning

confidence: 91%

See 1 more Smart Citation

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation

Garfall

Kim

Sun

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

mentioning

confidence: 91%

“…9 AML patients seemed to have benefited disproportionately from incompatibility. Most patients received myeloablative conditioning.…”

mentioning

confidence: 99%

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation

Garfall

Kim

Sun

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Several subsequent studies analyzing the impact of killer cell immunoglobulin-like receptors on outcome have had varied conclusions, which have been reviewed and put into context by others. [50][51][52] At this time, more information is needed to understand the role of this complex system in transplantation outcome. Donor selection based on killer cell immunoglobulin-like receptors should only be considered within the context of a clinical trial.…”

Section: Should Targets Of Nk Cell Alloreactivity Be Considered?mentioning

confidence: 99%

A perspective on the selection of unrelated donors and cord blood units for transplantation

Spellman

Eapen

Logan

et al. 2012

Blood

134

View full text Add to dashboard Cite

“…In allo-HSCT, NK cells have been recognized as a novel factor in the effector system that can overcome natural alloreactive T-cell barriers (6). Alloreactive donor NK cells facilitate engraftment by ablating different cells including residual leukemic cells, APCs, and T cells responsible for triggering GVHD (4,5,(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation

2018

Turk J Med Sci

View full text Add to dashboard Cite

IntroductionAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is the definitive choice for treatment of highrisk hematologic malignancies, even in advanced stages (1,2). There is evidence that allogeneic HLA-matched transplantation for patients with lymphoblastic and myeloblastic leukemia is more effective than autogeneic transplantation, because allo-HSCT may induce the graftversus-leukemia (GVL) effect (3,4). The potential benefit of the GVL effect relies on the elimination of residual malignant cells through immunological antitumor effects, induced by alloreactive T and natural killer (NK) cells, which leads to a lower relapse rate in allo-HSCT patients with hematologic malignancies (3,5,6). Despite all the advantages of allo-HSCT, there are still some complications that limit the success of this important procedure, including the development of graft-versushost disease (GVHD) (7). Alloreactive cells in the graft are widely considered to mediate both the GVL effect and GVHD (8).Acute GVHD, a major source of morbidity in HSCT, is mediated by donor allogeneic cytotoxic T cells against host tissues and leads to the recruitment of other effector cells including NK cells (9,10). The pathophysiology of acute GVHD has been described as a three-phase phenomenon: activation of donor-derived T cells, effector phase through Background/aim: After allogeneic hematopoietic stem cell transplantation (allo-HSCT), donor natural killer (NK) cells trigger alloreactions against potential recipient cells by their killer immunoglobulin-like receptors (KIRs). This study investigated whether KIR/HLA genotypes and KIR haplotypes of donors and recipients exhibit a critical function in the prevalence of acute graft-versus-host disease (aGVHD) and persistence of the graft after HLA-identical sibling allo-HSCT for patients with hematological malignancies. Materials and methods:We studied KIR and HLA genotypes in 115 related donors and recipients (56 patients with AML and 59 patients with ALL) who had received allo-HSCT from HLA-matched sibling donors. We evaluated 17 KIR genes and some alleles, including their ligands, using the PCR-SSP assay.Results: KIR gene frequency results between donors and recipients showed that donors had more activating KIR than their recipients. Chi-square comparison of KIR genotype frequencies in donors versus recipients revealed a significant difference (P < 0.001). We found a survival association between the donor lacking and the recipient having group B KIR haplotypes, although this was not statistically significant. Conclusion:This study suggests that we could exploit NK cell alloreactivity as a part of the optimization of donor selection and potential immunotherapeutic regimens to help facilitate good engraftment and reduce the risk of aGVHD incidence after allo-HSCT.

show abstract

Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?

Cited by 21 publications

References 46 publications

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation

A perspective on the selection of unrelated donors and cord blood units for transplantation

The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation

Contact Info

Product

Resources

About